HRP930685B2 - Postupak za laktonizaciju mevinskih kiselina i njihovih analoga - Google Patents

Postupak za laktonizaciju mevinskih kiselina i njihovih analoga

Info

Publication number
HRP930685B2
HRP930685B2 HRP930685AA HRP930685A HRP930685B2 HR P930685 B2 HRP930685 B2 HR P930685B2 HR P930685A A HRP930685A A HR P930685AA HR P930685 A HRP930685 A HR P930685A HR P930685 B2 HRP930685 B2 HR P930685B2
Authority
HR
Croatia
Prior art keywords
lactonization
analogs
mevinic
acids
mevinic acids
Prior art date
Application number
HRP930685AA
Other languages
English (en)
Croatian (hr)
Inventor
Laszlo R. Treiber
Original Assignee
Merck And Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22827965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP930685(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck And Co. Inc. filed Critical Merck And Co. Inc.
Publication of HRP930685A2 publication Critical patent/HRP930685A2/xx
Publication of HRP930685B1 publication Critical patent/HRP930685B1/xx
Publication of HRP930685B2 publication Critical patent/HRP930685B2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HRP930685AA 1988-07-19 1993-04-02 Postupak za laktonizaciju mevinskih kiselina i njihovih analoga HRP930685B2 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/221,475 US4916239A (en) 1988-07-19 1988-07-19 Process for the lactonization of mevinic acids and analogs thereof
YU136289A YU47492B (sh) 1988-07-19 1989-07-10 Postupak za laktonizaciju mevinskih kiselina i analoga istih

Publications (3)

Publication Number Publication Date
HRP930685A2 HRP930685A2 (en) 1998-06-30
HRP930685B1 HRP930685B1 (en) 1999-06-30
HRP930685B2 true HRP930685B2 (hr) 2006-11-30

Family

ID=22827965

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP930685AA HRP930685B2 (hr) 1988-07-19 1993-04-02 Postupak za laktonizaciju mevinskih kiselina i njihovih analoga

Country Status (26)

Country Link
US (1) US4916239A (Direct)
EP (1) EP0351918B1 (Direct)
JP (3) JPH0273078A (Direct)
KR (1) KR970011286B1 (Direct)
CN (1) CN1022831C (Direct)
AT (1) ATE111459T1 (Direct)
AU (1) AU609319B2 (Direct)
CA (1) CA1287639C (Direct)
CS (1) CS274640B2 (Direct)
CY (1) CY1813A (Direct)
DE (1) DE68918191C5 (Direct)
DK (1) DK173115B1 (Direct)
ES (1) ES2058475T3 (Direct)
FI (1) FI92695C (Direct)
HK (1) HK136894A (Direct)
HR (1) HRP930685B2 (Direct)
HU (2) HU202511B (Direct)
IE (1) IE64304B1 (Direct)
IL (1) IL90925A (Direct)
LV (1) LV11033B (Direct)
NO (1) NO172800C (Direct)
NZ (1) NZ229879A (Direct)
PT (1) PT91191B (Direct)
SI (1) SI8911362A (Direct)
YU (1) YU47492B (Direct)
ZA (1) ZA895458B (Direct)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
GB9007738D0 (en) * 1990-04-05 1990-06-06 British Bio Technology Compounds
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
US5250435A (en) * 1991-06-04 1993-10-05 Merck & Co., Inc. Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I)
AU660132B2 (en) * 1992-12-21 1995-06-08 Bayer Aktiengesellschaft Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
DE69324504T2 (de) * 1993-01-19 1999-08-26 Warner-Lambert Co. Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
IN186880B (Direct) * 1997-10-28 2001-12-01 Ranbaxy Lab Ltd
IN186879B (Direct) * 1997-10-28 2001-12-01 Ranbaxy Lab Ltd
ZA9810764B (en) * 1998-04-22 1999-08-13 Ranbaxy Lab Ltd An improved process of lactonization in the preparation of statins.
CA2240983A1 (en) 1998-06-18 1999-12-18 Yong Tao Process to manufacture simvastatin and intermediates
CZ299522B6 (cs) * 1998-12-10 2008-08-27 Kaneka Corporation Zpusob výroby diolu obsahujícího laktonovou skupinu
SK282679B6 (sk) * 1999-04-16 2002-11-06 Biotika, A. S. Spôsob izolácie lovastatínu z vyfermentovanej pôdy
EP1110959A4 (en) * 1999-06-29 2001-12-05 Kaneka Corp METHOD FOR SELECTIVE LACTONIZATION
AU8030900A (en) 1999-10-27 2001-05-08 Merck & Co., Inc. Lactonization process
DE01913139T1 (de) 2000-03-03 2005-03-31 Plus Chemical S.A. Ein verfahren zur reinigung von lovastatin und simvastatin mit verringertem gehalt an dimeren verunreinigungen
NL1017548C2 (nl) * 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
US6797831B2 (en) * 2001-05-18 2004-09-28 Aurobindo Pharma Limited Process for lactonization to produce simvastatin
KR100407758B1 (ko) 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
KR100502834B1 (ko) * 2002-03-25 2005-07-20 보령제약 주식회사 개선된 락톤화 반응에 의한 심바스타틴의 제조방법 및이의 정제방법
CA2480325A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Solid forms of salts with tyrosine kinase activity
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
US6995277B2 (en) 2003-02-11 2006-02-07 Plus Chemicals, B.V. Process for preparing simvastatin having controlled ranges of simvastatin dimer content
WO2005019161A1 (en) 2003-08-21 2005-03-03 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
BRPI0416639A (pt) 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
EP1732912B1 (en) * 2004-03-30 2008-11-12 Lupin Ltd. An improved method for manufacture of 4-hydroxy pyran-2-one derivatives
EP1786765B1 (en) * 2004-09-08 2009-09-02 Jubilant Organosys Limited An improved process for lactonization in the preparation of statins
CA2581596A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
WO2006059346A2 (en) * 2004-12-01 2006-06-08 Morepen Laboratories Limited An improved process for lactonization to produce highly pure statins
BRPI0518874A2 (pt) 2004-12-09 2008-12-16 Merck & Co Inc composto, composiÇço farmacÊutica, e, usos de um composto, e de uma composiÇço
DK1855674T3 (da) 2005-03-02 2014-10-20 Merck Sharp & Dohme Sammensætning til hæmning af cathepsin k
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
EP1741427A1 (en) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
WO2007020079A2 (en) * 2005-08-17 2007-02-22 Synthon B.V. Orally disintegratable simvastatin tablets
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
US20070117996A1 (en) * 2005-11-21 2007-05-24 Srinivasulu Gudipati Process for preparing simvastatin
EP1965862A2 (en) * 2005-12-21 2008-09-10 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
US20070161578A1 (en) * 2005-12-21 2007-07-12 Hwa Joyce J Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
TW200813039A (en) 2006-04-19 2008-03-16 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
JP2010502702A (ja) * 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2674436C (en) 2007-01-10 2012-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
AU2008221263B2 (en) 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
JP5378362B2 (ja) 2007-05-21 2013-12-25 ノバルティス アーゲー Ｃｓｆ−１ｒ阻害剤、組成物および使用方法
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090048335A1 (en) * 2007-08-17 2009-02-19 Venkata Naga Mandava Process for preparing simvastatin
DK2222636T3 (da) 2007-12-21 2013-06-03 Ligand Pharm Inc Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf
JP5492790B2 (ja) * 2008-02-27 2014-05-14 トーメン メディカル アーゲー インプラント及びその製造方法
EP2204170A1 (en) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
CN104098537A (zh) * 2009-11-20 2014-10-15 北大医药股份有限公司 制备他汀类化合物的内酯化方法
CN101704808A (zh) 2009-11-20 2010-05-12 西南合成制药股份有限公司 制备他汀类化合物的内酯化方法
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
HRP20191232T1 (hr) 2010-08-17 2019-11-01 Sirna Therapeutics Inc Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
CA139852S (en) 2010-10-15 2011-11-23 Reno de Medici SpA Christmas tree
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
AU2012245455A1 (en) 2011-04-21 2013-10-31 Merck Sharp & Dohme Corp. Insulin-Like Growth Factor-1 Receptor inhibitors
WO2013031729A1 (ja) 2011-08-26 2013-03-07 国立大学法人大阪大学 糖尿病性心血管合併症の予防・治療剤
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2597092A1 (en) 2011-11-24 2013-05-29 Sterling Biotech Limited A process for purification of lovastatin
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
AU2014332250B2 (en) 2013-10-08 2018-07-19 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015108988A2 (en) 2014-01-17 2015-07-23 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
CN112805006B (zh) 2018-08-07 2024-09-24 默沙东有限责任公司 Prmt5抑制剂
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
CN114096522A (zh) 2019-04-19 2022-02-25 利亘制药公司 化合物的晶型和制备化合物的晶型的方法
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20230108114A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
KR20250152667A (ko) 2023-03-02 2025-10-23 카르치문 바이오테크 게엠베하 암 및/또는 급성 염증성 질환을 진단하는 수단 및 방법
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0183132A2 (en) * 1984-11-19 1986-06-04 Merck Frosst Canada Inc. A process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
EP0232997A1 (en) * 1986-01-31 1987-08-19 Merck & Co. Inc. Antihypercholesterolemic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA81703B (en) * 1980-02-04 1982-09-29 Merck & Co Inc New antihypercholesterolemic compounds,intermediates and processes
JPS5948418A (ja) * 1982-09-10 1984-03-19 Sankyo Co Ltd 高血清過酸化脂質血症治療剤
US4582915A (en) * 1983-10-11 1986-04-15 Merck & Co., Inc. Process for C-methylation of 2-methylbutyrates
US4611067A (en) * 1985-01-31 1986-09-09 Merck & Co., Inc. Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
PT85109A (en) * 1986-06-23 1987-07-01 Merck & Co Inc Process for the preparation of hydroxy-tetrahydropyranone derivatives or corresponding ring opened dihydroxy acids which are hmg-coa reductase inhibitors
US4857546A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0183132A2 (en) * 1984-11-19 1986-06-04 Merck Frosst Canada Inc. A process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
EP0232997A1 (en) * 1986-01-31 1987-08-19 Merck & Co. Inc. Antihypercholesterolemic compounds

Also Published As

Publication number Publication date
KR970011286B1 (ko) 1997-07-09
IL90925A0 (en) 1990-02-09
JPH0273078A (ja) 1990-03-13
PT91191B (pt) 1995-03-01
CN1022831C (zh) 1993-11-24
YU47492B (sh) 1995-10-03
LV11033B (en) 1996-06-20
CA1287639C (en) 1991-08-13
DE68918191C5 (de) 2005-06-09
FI893363A0 (fi) 1989-07-11
HU202511B (en) 1991-03-28
JPH09188672A (ja) 1997-07-22
IL90925A (en) 1993-04-04
ZA895458B (en) 1990-03-28
FI92695B (fi) 1994-09-15
DK354189A (da) 1990-01-22
ES2058475T3 (es) 1994-11-01
CY1813A (en) 1995-10-20
CS435489A2 (en) 1990-12-13
JPH07196642A (ja) 1995-08-01
CN1039420A (zh) 1990-02-07
DK354189D0 (da) 1989-07-18
IE64304B1 (en) 1995-07-26
KR910002828A (ko) 1991-02-26
NZ229879A (en) 1991-12-23
SI8911362A (en) 1997-02-28
NO892938L (no) 1990-01-22
YU136289A (en) 1991-02-28
EP0351918A1 (en) 1990-01-24
DE68918191D1 (de) 1994-10-20
FI92695C (fi) 1994-12-27
NO892938D0 (no) 1989-07-17
JPH0575752B2 (Direct) 1993-10-21
PT91191A (pt) 1990-02-08
FI893363A7 (fi) 1990-01-20
AU609319B2 (en) 1991-04-26
NO172800C (no) 1993-09-08
LV11033A (lv) 1996-02-20
IE892324L (en) 1990-01-19
NO172800B (no) 1993-06-01
US4916239A (en) 1990-04-10
HUT50804A (en) 1990-03-28
CS274640B2 (en) 1991-09-15
HU210533A9 (en) 1995-04-28
IE892324A1 (en) 1991-06-19
EP0351918B1 (en) 1994-09-14
HRP930685B1 (en) 1999-06-30
DE68918191T2 (de) 1995-03-02
HRP930685A2 (en) 1998-06-30
HK136894A (en) 1994-12-09
DK173115B1 (da) 2000-01-31
AU3824089A (en) 1990-01-25
JP2718422B2 (ja) 1998-02-25
ATE111459T1 (de) 1994-09-15

Similar Documents

Publication Publication Date Title
HRP930685A2 (en) Process for the lactonization of mevinic acids and analogs thereof
HUT63419A (en) Process for producing mercaptoacetamide derivatives of pyrrolo-, pyrido- and oxazinobenzazepine having encephalinase- and angiotensin-converting enzyme-inhibiting activity
PT83077A (en) Process for preparing compactin and mevinolin analogs useful as hmg-coa reductase inhibitors
AU5027393A (en) Benzo-fused lactams
GB8811929D0 (en) Phosphorus-containing hmg-coa reductase inhibitors new intermediates & method
JPS6426535A (en) Novel hmg-coa reductase inhibitor
ES8800244A1 (es) Un procedimiento para preparar naftiridinas antibacterianas
EP0430336A3 (en) Process for the preparation of 4-o-phosphates of dopamine and dopamine derivatives
GR3030718T3 (en) Novel prostaglandin analogue.
GB8811931D0 (en) Phosphorus-containing hmg-coa reductase inhibitors new intermediates & method
NO924690D0 (no) Fremgangsmaate for fremstilling av mono-n-substituerte tetraazakrocykluser
EP0578761A4 (en) ENZYMATIC PROCESS FOR PRODUCING CEFONICIDE.
EP0283123A3 (en) Intermediates and process useful in the preparation of hmg-coa reductase inhibitors
EP0349060A3 (en) Process for the formation of 6-desmethyl-6-exo-methylene derivatives of lovastatin and analogs thereof
EP0210589A3 (en) Process for preparing optically active carboxylic acids and relative intermediates
GR3006806T3 (Direct)
GR3007199T3 (Direct)
IL104135A0 (en) Process for the manufacture of halomaleic and halofumaric esters

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPN Proposal for the declaration of nullity of a patent
PDOP Patent surrendered in part
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060704

Year of fee payment: 18

B2IS Complete republication of hr-b document after nullification/surrender
PBON Lapse due to non-payment of renewal fee

Effective date: 20070711

PPNO Proposal for the declaration of nullity of a patent rejected/refused